Loading…

Immunoreactivity in mammals of two typical plant glyco-epitopes, core α(1,3)-fucose and core xylose

The presence of nonmammalian core α(1,3)-fucose and core xylose glyco-epitopes on glycans N-linked to therapeutic glycoproteins produced in plants has raised the question of their immunogenicity in human therapy. We address this question by studying the distribution of these N-glycans in pea, rice,...

Full description

Saved in:
Bibliographic Details
Published in:Glycobiology (Oxford) 2003-06, Vol.13 (6), p.427-434
Main Authors: Bardor, Muriel, Faveeuw, Christelle, Fitchette, Anne-Catherine, Gilbert, Danièle, Galas, Ludovic, Trottein, François, Faye, Loïc, Lerouge, Patrice
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The presence of nonmammalian core α(1,3)-fucose and core xylose glyco-epitopes on glycans N-linked to therapeutic glycoproteins produced in plants has raised the question of their immunogenicity in human therapy. We address this question by studying the distribution of these N-glycans in pea, rice, and maize (which are the crops intended for the production of therapeutic proteins) and by reinvestigating their immunogenicity in rodents. We found that immunization with a model glycoprotein, horseradish peroxidase, elicits in C57BL/6 mice and rats the production of antibodies (Abs) specific for core α(1,3)-fucose and core xylose epitopes. Furthermore, we demonstrated that about 50% of nonallergic blood donors contains in their sera Abs specific for core xylose, whereas 25% have Abs against core α(1,3)-fucose. These Abs probably result from sensitization to environmental antigens. Although the immunological significance of these data is too speculative at the moment, the presence of such Abs might introduce some limitations to the use of plant-derived biopharmaceutical glycoproteins, such as an accelerated clearance during human therapy.
ISSN:0959-6658
1460-2423
1460-2423
DOI:10.1093/glycob/cwg024